Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Hepatic Function
This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities.
The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 1, open-label, multicenter, single-dose, parallel-group, non-randomized trial to evaluate the PK, safety, and tolerability of petrelintide after a single dose in participants with mild, moderate, or severe HI, and participants with normal hepatic function. Allocation of participants to the hepatic function groups will be based on Child-Pugh classification.
Each participant will receive a single subcutaneous (SC) dose of petrelintide on Day 1.
Up to 18 participants with normal hepatic function and 18 participants with HI (6 participants each in the following groups: mild, moderate, or severe HI) will participate in this trial.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Clinical Trial Information Desk
- Telefonnummer: +4588773600
- E-post: clinicaltrials@zealandpharma.com
Studieorter
-
-
Poland
-
Wroclaw, Poland, Polen, 51-162
- Rekrytering
- Centrum Badań Klinicznych Piotr Napora lekarze sp.p.
-
Kontakt:
- Piotr Napora, Dr.
- Telefonnummer: +483267900
- E-post: napora.piotr@cbk.wroc.pl
-
-
-
-
Bratislava Region
-
Bratislava, Bratislava Region, Slovakien, 831 01
- Rekrytering
- Summit Clinical Research s.r.o.
-
Kontakt:
- Viera Kupčová, Dr.
- Telefonnummer: +421905286213
- E-post: viera.kupcova@summit-cr.eu
-
-
Malacky
-
Malacky, Malacky, Slovakien, 901 01
- Rekrytering
- Summit Clinical Research s.r.o.
-
Kontakt:
- Edita Kadlubiaková, Dr.
- Telefonnummer: +421905434699
- E-post: edita.kadlubiakova@summit-cr.eu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
All participants:
- Sex: male and female participants.
Body mass index (BMI): 18.5 to 40.0 kg/m^2, inclusive, at screening.
Additional Inclusion Criteria for Participants with Normal Hepatic Function
- Participants who are considered healthy as determined by medical history, physical examination, and other screening procedures, with clinically normal hepatic function at screening..
Clinical laboratory test results within normal reference range for the population, or results with acceptable deviations that are judged not to be clinically significant by the Investigator.
Additional Inclusion Criteria for Participants with Hepatic Impairment
- Participants with stable HI for at least 3 months, classified as Child-Pugh Grade A, B, or C as assessed by the Investigator.
- Participants should be otherwise judged to be in acceptable health (type 2 diabetes mellitus [T2DM] is allowed) in the opinion of the Investigator based on a medical evaluation (including a physical examination, medical history, electrocardiogram [ECG], vital signs, concomitant medication and the results of laboratory safety tests) performed during the screening visit.
- Participants with T2DM may be enrolled if they have/are: a. Hemoglobin A1c ≤11% at screening b. On a stable regimen for at least 8 weeks prior to screening, defined as: stable diet and exercise program, and/or, stable dose of metformin, and/or, stable dose of a sodium-glucose cotransporter-2 inhibitor.
Exclusion Criteria:
All participants:
- Known or suspected hypersensitivity to the IMP or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Petrelintide: Normal Hepatic Function
Participants with normal hepatic function will receive a single SC dose of petrelintide.
|
Petrelintide will be administered as a single SC injection.
Andra namn:
|
|
Experimentell: Petrelintide: Mild HI
Participants with mild HI will receive a single SC dose of petrelintide.
|
Petrelintide will be administered as a single SC injection.
Andra namn:
|
|
Experimentell: Petrelintide: Moderate HI
Participants with moderate HI will receive a single SC dose of petrelintide.
|
Petrelintide will be administered as a single SC injection.
Andra namn:
|
|
Experimentell: Petrelintide: Severe HI
Participants with severe HI will receive a single SC dose of petrelintide.
|
Petrelintide will be administered as a single SC injection.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Infinity (AUC0-inf) of Petrelintide
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
AUC from Time Zero up to Time of Last Measurable Concentration (AUC0-last) of Petrelintide
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
|
Maximum Observed Plasma Concentration (Cmax) of Petrelintide
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
|
Time to Cmax (tmax)
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
|
Apparent Clearance (CL/F) of Petrelintide
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
|
Terminal Elimination Half-life (t1/2) of Petrelintide
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
|
Apparent Volume of Distribution at Terminal Phase (Vz/F) of Petrelintide
Tidsram: Day 1 (pre-dose) to Day 50 (Follow-up)
|
Day 1 (pre-dose) to Day 50 (Follow-up)
|
|
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Tidsram: Day 1 up to Day 50
|
Day 1 up to Day 50
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Clinical Trial Information Desk, Zealand Pharma A/S
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- ZP8396-25077
- Universal Trial number (Annan identifierare: U1111-1328-8578)
- 2025-523641-10-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .